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ABSTRACT 
This study compared the molecular lipidomic profile of LDL in patients with non-diabetic 
advanced renal disease and no evidence of cardiovascular disease to that of age-matched 
controls, with the hypothesis that it would reveal proatherogenic lipid alterations. LDL was 
isolated from 10 normocholesterolemic patients with stages 4/5 renal disease and 10 controls, 
and lipids were analysed by accurate mass liquid chromatography-mass spectrometry. Top-down 
lipidomics analysis and manual examination of the data identified 352 lipid species, and 
automated comparative analysis demonstrated alterations in lipid profile in disease. The total 
lipid and cholesterol content was unchanged, but levels of triacylglycerides and N-acyltaurines 
were significantly increased, while phosphatidylcholines, plasmenyl ethanolamines, sulfatides, 
ceramides and cholesterol sulfate were significantly decreased in CKD patients. Chemometric 
analysis of individual lipid species showed very good discrimination of control and disease 
sample despite the small cohorts, and identified individual unsaturated phospholipids and 
triglycerides mainly responsible for the discrimination.  These findings illustrate the point that 
although the clinical biochemistry parameters may not appear abnormal, there may be important 
underlying lipidomic changes that contribute to disease pathology. The lipidomic profile of CKD 
LDL offers potential for new biomarkers and novel insights into lipid metabolism and 
cardiovascular risk in this disease. 
 
Keywords 
Cholesterol, Dyslipidemias, Inflammation, Phospholipids, Mass spectrometry; 
Cholesterol sulfate, N-acyltaurine, Partial least squares discriminant analysis. 
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Introduction 
Chronic kidney disease (CKD) is a serious and increasingly common condition (1). 
Patients with CKD have a greatly increased risk of cardiovascular disease (CVD), which 
represents the most common cause of mortality and morbidity in these patients, to the extent that 
CKD is considered an independent risk factor for CVD (2, 3). In CKD, many conventional risk 
factors for CVD are prevalent, including hypertension, dyslipidemia and insulin resistance. 
Underlying conditions that are typical of CVD also occur, such as heightened inflammatory 
status, oxidative stress, endothelial dysfunction and arterial stiffness (3, 4). Consequently, 
understanding the factors in CKD that could contribute to increased CVD risk is very important. 
In CVD there is a clearly established link between dyslipidemia (specifically 
hypercholesterolemia and hypertriglyceridemia) and atherosclerosis, an underlying pathology of 
most CVD (5, 6). In view of the clear cardio-renal relationship, there has been considerable 
interest in the possible contribution of hyperlipidemia to CKD-associated CVD (7, 8).  The 
nature of this lipid imbalance is significantly different to non-renal-related CVD; in particular, 
the relationship with cholesterol level is less clear than in the general population and is 
dependent on the stage of disease (9, 10). In some patients, total cholesterol and LDL-cholesterol 
are not elevated, while patients on hemodialysis may even have reduced cholesterol compared to 
control subjects (11).  It is apparent that CKD involves multiple lipid abnormalities, some of 
which may contribute to increased CVD risk. However, most studies of lipid abnormalities in 
CKD have focused on lipoprotein profile or on overall lipid classes such as triglycerides. Whilst 
in many inflammatory diseases, including pre-eclampsia (12), diabetes (13), rheumatoid arthritis 
(14) and Crohn’s disease (15), lipidomic studies have identified characteristic lipid signatures 
that have potential as diagnostic tools, there have as yet been few attempts at profiling individual 
lipids in CKD. Evidence for an altered phospholipid profile in CKD (16) and a decrease of serum 
sulfatide levels in patients with end-stage renal failure (17) have been reported, but otherwise 
little is known about molecular changes.  
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Modern lipidomics depends almost entirely on analysis by electrospray mass 
spectrometry, as this is able to identify a very wide variety of individual lipid species in several 
classes. Both shotgun lipidomics, involving direct infusion of the sample into the instrument, and 
liquid chromatography coupled to mass spectrometry (LC-MS) are widely used for this purpose 
(18). Chromatographic separation provides additional information to facilitate lipid 
identification, and separation of the lipids reduces interference (19). Although with lower 
resolution instruments, tandem MS is necessary to distinguish lipids of similar mass but different 
formula, modern high resolution instruments such as orbitraps offer sufficient mass accuracy that 
isobaric species can be distinguished, thus allowing classification of lipid analytes and 
identification of the total number of carbons and double bonds in the acyl chains by a top-down 
approach (20). It has been demonstrated that this untargetted approach, coupled with principle 
component analysis, can be used without internal standards for comparative analysis of 
lipidomes, owing to the high dynamic range of the orbitrap (21). Similar “semi-quantitative” 
approaches on a triple quadrupole instrument have also been used for comparative lipidomics in 
cardiovascular disease (22, 23). However, tandem MS or MSn is still required for confirmation of 
individual acyl chain length and double bonds. 
We recently demonstrated that a top-down lipidomics approach using liquid 
chromatography interfaced to mass spectrometry on a high resolution instrument (Orbitrap 
Exactive) was able to identify more than 350 individual lipid species or isomeric lipid clusters in 
normo-lipidemic LDL (24). The lipids were identified by matching the experimental m/z for the 
molecular ions to calculated mono-isotopic masses available in lipidomic and metabolic 
databases.   LDL is an important carrier of a wide variety of lipid species within the plasma, and 
reflects systemic changes in lipid metabolism. We hypothesized that the application of this 
methodology to CKD would identify novel differences in lipid profile at a molecular level 
between disease and control samples that would enhance understanding of the disease 
mechanisms and offer potential as diagnostic markers. 
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MATERIALS AND METHODS 
Materials 
All chemicals used were of analytical quality and purchased from Sigma-Aldrich (UK) or 
ThermoFisher (UK) unless stated otherwise. Organic solvents were HPLC grade purchased from 
Fisher Scientific (Loughborough, UK).  
Subjects and blood collection 
Male CKD patients (stage 4/5) were recruited from the renal outpatient clinic at the 
Royal Infirmary of Edinburgh following ethical approval by NHS Lothian Research Ethics 
Committee and gave informed consent as described previously (25). Renal patients were 
excluded on the basis of renal transplant, dialysis, systemic vasculitis or connective tissue 
disease, a history of established cardiovascular disease, peripheral vascular disease, diabetes 
mellitus, respiratory disease, neurological disease, alcohol abuse or treatment with an organic 
nitrate or β-agonist. The causes of kidney disease in patients were autosomal dominant 
polycystic kidney disease (n=4), IgA nephropathy (n=2), reflux nephropathy (n=3) and 
neurogenic bladder (n=1). Smokers and hypercholesterolemic patients were not excluded, but the 
latter were controlled by statin medication (2 individuals in the disease group) and stable on 
treatment for 3 months prior to inclusion in the study. Subjects refrained from alcohol for at least 
24h, and caffeinated drinks and smoking for at least 12 h before the study.  
Blood samples were collected in polypropylene tubes containing EDTA (final 
concentration, 1 mg/mL of blood), plasma was promptly separated by centrifugation (2500xg, 20 
min, 4°C) and stored in 2 mL aliquots at -80°C in the dark.  
Clinical and biochemical measurements 
Blood pressure, hsCRP, OxLDL and IL-6 were determined as described previously (25). 
Other parameters (plasma glucose, total cholesterol, triglyceride, lipoproteins, creatinine and 
glycated hemoglobin (HbA1c)) were determined in the hospital biochemistry laboratory by 
assays validated to GLP standard.  
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Plasma samples and LDL separation 
LDL was isolated from plasma aliquots essentially as described previously (26). KBr 
(0.3816 mg) was dissolved in 1 mL of plasma at 4oC, and underlaid below 4.1 ml of a 
deoxygenated EDTA solution, before centrifuging in a Beckman VTi 90 rotor for 2 hours at 
60,000 rpm to generate a density gradient. LDL formed bands in the density range 1.019-1.060 
g/mL. The LDL collected was stored in sterile vials under nitrogen, and desalted before 
determining the cholesterol content using CHOL PAD reagent (Roche Diagnostics) and protein 
concentration of isolated LDL was determined by the Bradford assay as reported by Yue et al. 
(27). Purity of isolated LDL was confirmed by polyacrylamide gel electrophoresis (24, 28). 
Vitamin E content 
Vitamin E content (α-tocopherol) in LDL was determined by reverse-phase 
chromatography using spectrophotometric detection as described previously (29). The samples 
and standards were injected randomly in triplicate and area under the curve (AUC) was plotted 
against the calibration curves and used to calculate the concentration of vitamin E in the samples 
(µg/mg protein). Standards (0.1-10 µg/mL), made up in methanol and extracts redissolved in 100 
µL methanol, were analysed in triplicate by injection of 20µL. The intraday CV (n=3) at a 
concentration of 2.5 μg/mL was 3.1%. Statistical analysis was carried out using an unpaired t 
test, with Welch's correction to estimate the p values. 
Electrophoretic mobility of LDL 
The particle size of LDL was assessed by 1% agarose gel electrophoresis in barbital 
buffer as described previously (30). Retardation factors (Rf) were defined as the distance (cm) 
travelled by sample / distance (cm) travelled by dye front. 
Lipid Extraction 
LDL lipids were extracted from LDL containing 25 μg protein by the Folch method as 
described recently (24). The lipid extracts were combined into an amber vial (Supelco), dried 
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under a stream of nitrogen filtered with a 0.22 µm mesh (Millipore) and stored at -70°C until 
further analysis. Mean recovery (%) of PC (13:0/13:0) lipid standard in spiked LDL samples by 
the Folch method was 103.9±8.6. Similar recoveries were achieved with dehydroepiandrosterone 
sulfate as a representative of more polar lipid classes, and d5-myristic acid (Sigma Aldrich 
Chemical Co, UK) as a representative of less polar lipids. 
Top-down LC-MS analysis of lipidomic profile 
Lipid extracts were solubilized in 100 µL CHCl3:MeOH (1:1, v/v), further diluted in 
MeOH and analysed by LC-MS essentially as described previously (24). Separation of LDL lipid 
classes was performed using a Dionex Ultimate 3000 HPLC system (Thermo Scientific, Hemel 
Hempstead) by injection of 10 μL sample onto a silica gel column (150mm x 3mm x 3µm, 
HiChrom, Reading, UK) used in hydrophilic interaction chromatography (HILIC) mode (24). 
Two solvents were used: (A) 20% isopropyl alcohol (IPA) in acetonitrile and (B) 20% IPA in 
ammonium formate (20 mM). Elution was achieved using the following gradient at 0.3 mL/min: 
elution at 5% B for 1 min, followed by a rise to 9% B at 5 min, to 15% B at 10 min, to 25% B at 
16 min, to 35% B at 23 min, and from 28-40 min a decrease to 5% B. Detection of lipids was 
performed in a Orbitrap Exactive Mass Spectrometer (ThermoFisher Scientific Inc., Bremen, 
Germany) equipped with polarity switching. The instrument was calibrated according to the 
manufacturer specifications to give an rms mass error <2 ppm. The following electrospray 
ionization settings were used: source voltage: ±4.50 kV, capillary voltage: 25 V, capillary temp: 
320oC, sheath gas flow: 50 AU, aux gas flow: 17 AU, sweep gas flow: 0 AU. All LC-MS spectra 
were recorded in the m/z range 100-1200 at 50,000 resolution (FWHM at m/z =500). Three 
microscans were collected per data point with the injection time limited by either an automatic 
gain control target ion intensity of 106 or a maximum inject time of 250 ms.   
For certain lipids of interest, tandem mass spectrometry (MS2) was carried out on an LTQ 
Orbitrap instrument (ThermoElectron, Hemel Hempstead, UK) controlled by Xcalibur (version 
2.0, Thermo Fisher Corporation) in either positive or negative ion modes as appropriate for the 
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best detection of the parent ion. The capillary voltage was set at 4.5kV, capillary temperature at 
275°C, with sheath gas and sweep gas flow rates set at 30 and 10 AU respectively. Collision 
energy was set according to the ion of interest, typically between 25-35 (arbitrary units). 
 
LC-MS data processing  
In the first stage, LC-MS data were analysed and lipid species identified by manual 
matching of retention times and accurate mass data to a home-built database and the Human 
Metabolome project database (HMDB) (31), with identifications based on ions showing a mass 
error of <5 ppm (and in most cases <2 ppm) to the mono-isotopic mass calculated from the 
theoretical formula. 352 lipids were identified by this approach.  
Subsequently, LC-MS data were analysed by filtering with MZMatch (32) followed by 
using the XCMS pipeline (XCMS Online version 0.0.83, Scripps Center for Metabolomics, 
https://xcmsonline.scripps.edu/, (33)) for peak detection, alignment and isotope annotation as 
described previously (24). Ions with intensity <5000 cps were excluded. Integration of features 
extracted in different samples corresponds to the reported extracted ion chromatogram areas.  
Peak intensities for the ions identified from individual lipid classes in the datasets were summed 
and used to evaluate overall differences in disease vs. age-matched control groups. Extracted 
features were included if they were present in >50% of the samples in each group, were within 
2.5 ppm from the exact mono-isotopic mass, and with < 5s retention time deviation. In order to 
prevent overestimation of the number of lipid species identified, all lipid species detected in 
positive and negative ion modes were manually cross-referenced. Overall, 142 and 158 
individual lipids were identified in positive and negative ion modes, respectively. Isomeric 
species are reported as one single ion, for instance PC(16:0/18:1), PC(18:1/16:0), PC(16:1/18:0), 
PC(18:0/16:1), PC(14:0/20:1) and others are expressed as PC(34:1). The data processing steps 
and number of features or lipids identified at each stage are summarized in Supplementary 
Figure 1. 
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Statistical analysis 
The merged data set comprising 300 lipids species (Supplementary Figure 1), were 
further analysed using Partial Least Squares Discriminant Analysis (PLSDA) (34, 35). PLSDA 
calibration models were validated using segmented cross-validation, and optimization of PLSDA 
models was achieved using the Variable Importance in Projection (VIP) score (36). A VIP cut-
off value of 0.8 was repeatedly applied to eliminate less discriminating variables, with a cut-off 
of 0.85 for the merged set. The final classification model included 48 species detected in the 
positive mode and 55 in the negative mode. The statistical significance of the classification 
PLSDA models was assessed using permutation testing with 1000 permutations (37). Q2 was 
used as quality-of-fit criterion for the permutation test (38). Further details are given in 
Supplemental methods. 
Statistical analysis of clinical and biochemical parameters was conducted using non-
parametric t-tests (Mann-Whitney) using two-tailed p value calculation, and values with p<0.05 
were considered statistically significant.  
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RESULTS 
Evaluation of clinical and biochemical parameters in kidney disease 
Baseline measurements of clinical and biochemical parameters for age- and body mass-
matched subjects included in this study are summarized in Table 1.  Glomerular filtration rate 
(GFR) was estimated using the MDRD equation and confirmed all patients as stage 4 or 5 CKD; 
they also had significantly increased systolic BP. There were no significant differences in levels 
of glycated hemoglobin and plasma glucose. The inflammatory marker C-reactive protein was 
significantly elevated, although IL-6 was not. The levels of total plasma cholesterol and LDL 
were not altered with CKD and there was no change in OxLDL.  In contrast, HDL levels showed 
a significant decrease and plasma triglycerides were elevated, as expected for patients with CKD 
and published previously (25). LDL vitamin E content and particle heterogeneity 
(electrophoretic mobility) were also determined but there was no statistical difference (Table 1).  
 
Analysis of LDL from control and CKD samples by manual matching to databases identified 
more than 300 different lipid species 
In order to investigate the lipidome of LDL from control and CKD patients, LDL extracts 
were analysed by normal-phase liquid chromatography mass spectrometry (LC-MS) in both 
positive and negative ion modes as reported previously (24). Representative chromatograms for 
control and CKD samples in each mode are shown in Figure 1. The various chromatographic 
peaks observed correspond to the elution of different lipid classes. Some lipid species were 
observed in both positive and negative ionization modes, as indicated by the appearance of peaks 
with the same retention times, notably in the retention time ranges 2-3.5 and 20.5-22.5 mins.  It 
can be seen that there were no gross changes in the profile of either positively or negatively 
charged lipids between sample types, although some minor changes in intensity of 
chromatographic peaks eluting with retention times shorter than 5 mins were apparent.  
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All features (ions) detected in the chromatograms using XCMS software were recorded 
by retention times, accurate mass/charge measurement and intensity, to generate a combined list 
of 1619 distinct features. Manual matching of the experimental values with theoretical databases 
was carried out to identify lipid species, as well as manual cross-checking for multiple adducted 
forms of some lipids (e.g. [MH]+, [MNa]+ or [M+NH4]+ in positive ion mode; [M-H]- and 
[M+HCOO]- in negative ion mode) to avoid duplication, and isomeric species are reported as 
one single ion.  A summary list corresponding to 352 individual lipid and lipid-related species 
covering 18 lipid classes or subclasses was compiled (Table 2), which were very similar to those 
reported previously in healthy volunteers (24). The full list of lipid species detected is given in 
Supplemental Table 1. 
 
Comparative analysis showed changes in CKD LDL lipid classes including cholesterol sulfate, 
sulfatides, ceramides and lysolipid ratios 
In order to investigate the hypothesis that changes in molecular composition of LDL 
occur in CKD, an automated analysis of the LC-MS data using the XCMS and MZMatch 
platform was undertaken. This procedure identified 300 lipid features, 142 in positive ion and 
158 in negative ion, which after manual cross-checking for remove adducts and duplicates 
corresponded to approximately two thirds of the lipid species identified by manual analysis. The 
smaller number of positive identifications results from several factors, including the exclusion of 
ions with intensity <5000 cps, the requirement that peaks were present in >50% of samples in 
either group, and the ability of the programme to adjust for minor differences in retention times.  
The intensities of ions identified in this dataset were summed to provide an estimate of 
the total lipid intensity and the lipid intensity in each of the identified classes, following a 
previously published procedure (24). The variability of total lipids extracted (extraction 
repeatability and analytical reproducibility) between replicates in the samples of control and 
disease group was <10%, thus enabling this approach to be used for comparisons of lipid content 
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between samples for any one lipid class, although it cannot be used for comparisons between 
lipid classes owing to differences in ionization efficiencies. 
The total lipid in LDL remained essentially unaltered in the CKD patient group compared 
to the age-matched control group (Figure 2a), but changes in the intensity of a number of lipid 
classes were observed in LDL. There was an observed statistically significant increase in 
triacylglycerides (Figure 2b), in agreement with the clinical data in Table 1, whereas the content 
of phosphatidylcholines decreased significantly in the CKD group (Figure 2c). There were no 
changes in the intensities of total cholesterol and sphingomyelins, or in the total levels of 
phosphatidylethanolamines (PE) (data not shown), although the contribution of PE containing a 
vinyl ether linkage to the total PE pool was significantly lower in CKD samples (Figure 2d). 
Interestingly, the total content of lyso-lipids (LPC+LPE) in LDL in disease patients was similar 
when compared to age-matched controls (Figure 2e), but the ratio of lyso-lipid types (LPC/LPE) 
showed a significant decrease in LDL from CKD samples (Figure 2f).  In addition, changes in 
CKD were observed in 4 other lipid class that constitute minor components of LDL; specifically, 
the content of ceramides (Figure 3a), cholesterol sulphate (Figure 3b) and sulfatides (Figure 3c) 
decreased significantly in LDL from CKD patients, whereas a significant increase was observed 
in the content of N-acyltaurines(Figure 3d). Thus in addition to changes in commonly assessed 
lipid class triglycerides, CKD patients show changes in both abundant and minor lipid 
components of LDL that are not apparent simply from standard lipoprotein assessment. 
 
Statistical analysis discriminated control and CKD LDL lipidomes based on individual species 
of unsaturated phospholipids and triglycerides. 
For a full statistical analysis of the MS data and to identify the contribution of individual 
lipid species to differences between the control and CKD samples, Partial Least Squares 
Discriminant Analysis (PLSDA) was used. The classification summary for three optimized 
models calculated using lipid profiles measured in positive and negative ion modes and the 
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merged (+ve plus –ve mode) data set, are shown in Table 3. Q2 values, which are a measure of 
the ability of the model to predict correctly the class, lie between 0.79 and 0.82.  Values of 0.5 
are often classed as acceptable, and 0.8 as good, for PLSDA analysis of datasets with a limited 
number of classes. The power of the discrimination is further illustrated by the PLSDA score 
plot for the merged data (Figure 4), which shows the samples from control and CKD cluster 
together, and that the classes are well separated from each other within the plot. Similar 
statistical results were obtained for all three data sets, with a correct classification rate 
(percentage of samples assigned to the correct class) between 94% and 98%, sensitivity (true 
positive rate, a measure of the proportion of positive correctly assigned) between 0.93 and 0.97, 
and specificity (true negative rate, a measure of the proportion of negatives correctly assigned) 
between 0.96 and 1 for the cross-validation data, though slightly better results were obtained 
using merged data (Table 3).  The closer the values are to 1 the better the quality of the model. 
The ions that contributed most strongly to the discrimination can be determined from their 
contribution to the PLSDA model, and were unsaturated lipid species from the most abundant 
lipid classes, namely PC, TAG and PE; the complete set of discriminating ions is indicated in 
Supplemental Table 2. Comparison of PLSDA score and loading plots obtained using the 
merged (+ve plus –ve mode) data set shows that higher levels of lipid species from the PE class 
and some species from TAG and SM classes are present in the samples from the disease group, 
while all other lipid species are present at lower concentration.  Two examples of the lipids that 
contributed strongly to the lipidomic alteration in LDL from CKD patients include plasmenyl PC 
40:7 at m/z 818.6060 (Figure 5a, decreased in CKD) and plasmenyl PE 38:7 at m/z 746.5137 
(Figure 5b, decreased in CKD).  
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Discussion 
 CKD is associated with increased risk of CVD and dyslipidemia contributes to this 
increased risk (2-4), but until recently studies of lipids in CKD have mainly focused on 
lipoprotein balance or measured total levels of major classes (7, 11, 39). To test the hypothesis 
that molecular information about LDL lipidomic profile would reveal novel details of 
dyslipidemia in CKD, we used a top-down lipidomic approach that allows a comparative 
analysis (20, 22, 23) of the LDL lipid profile from age-matched controls and patients with stage 
4/5 CKD. This identified significant differences in LDL lipidome of CKD patients.  Multivariant 
analysis by PLSDA showed very good discrimination of the control and disease data sets, with a 
combination of positively and negatively charged lipids providing the best discrimination. The 
lipid species that contributed most were specific isomeric clusters from the abundant lipid 
classes, namely phosphatidylcholines (decreased), triglycerides (increased) and 
plasmenylethanolamines (decreased as a proportion of total PE), as these contain a large number 
of individual lipids, many of which are known to be present at relatively high levels in LDL (40). 
However, minor lipid subclasses also showed significant differences in CKD and control LDL, 
specifically cholesterol sulphate, sulfatides, and ceramides, which were lower in CKD LDL, and 
N-acyltaurines, which increased in CKD LDL, compared to control. Thus although the clinical 
lipoprotein profile only showed an increase in triglycerides and a decrease in HDL, detailed 
molecular analysis identified several lipid classes and subclasses that are altered in LDL, and 
within these classes, changes in several molecular lipid species. 
 Some of the molecular changes observed in the LDL lipidome in CKD are linked to 
atherogenic mechanisms, and therefore could explain the increased risk of CVD in these patients. 
PCs are phospholipids present in the surface monolayer of LDL, and are important for the 
conformation of ApoB-100, macrostructure of LDL, and its correct interaction with LDL 
receptors (41, 42). Interestingly, the overall decreased PC observed in this study was apparently 
not sufficient to cause major structural changes in the LDL, as there was no significant change in 
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the size of the LDL particles in CKD. The decrease in PCs observed is in agreement with a 
previous report on levels of PC in plasma of end stage renal failure (ESRF) patients (43), and 
also with the observation that PCs are lost in urine of patients with CKD (44). The lower levels 
of sulfatides and cholesterol sulfates in LDL of CKD patients are in agreement with some 
previous studies (17). Sulfatides are anionic glycosphingolipids that are known to have anti-
thrombotic effects, although opposing effects have also been reported under certain experimental 
conditions (17, 45).  Within LDL, they confer negative charge at the particle surface and have 
been suggested to act as endogenous ligands for chemokines (46) and some selectins (47). Thus 
it is clear that they have complex effects within the cardiovascular system and decreased levels 
could upset delicately balanced processes such as thrombosis and LDL-endothelial cell 
interactions. Hu et al. (17) reported that sulfatides were the only factor that discriminated control 
from ESRF groups in their study, and that they have promise as biomarkers for CKD. We 
observed a decrease in the level of ceramides in LDL from CKD patients; however, as increased 
sphingomyelinase activity and free ceramides are thought to be linked to atherogenesis (48, 49), 
this does not appear to contribute to the pro-atherogenic profile of CKD. Finally, it was also 
noted that there was a significant increase in taurine-containing lipoamino acids (LAA) in LDL 
from CKD patients. LAAs are well known as components of mammalian nervous tissue and are 
involved in signaling neuronal events (50), and have only recently been detected in LDL (24). In 
neuronal ischemia these lipids have been reported to show protective and anti-inflammatory 
effects (51), but they can also induce apoptosis of macrophages (52). As yet, their role in 
lipoproteins and potential atherogenic contribution has not been elucidated.  
A limitation of this study is that only patients with severe kidney disease and age-
matched controls were compared, so, in the absence of intermediate stages, limited conclusions 
about the role of these changes in disease progression can be drawn. Also, the CKD patients 
studied here had minimal comorbidity with no current clinically apparent CVD, despite the high 
risk of developing CVD.  Although in this cohort the levels of hsCRP were high, indicating some 
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inflammation, IL-6 and measures of oxidative stress (OxLDL) were low. These findings differ 
from some previous studies (3, 4) where both inflammation and oxidative stress were 
substantially increased in CKD and contribute significantly to its accelerated vascular pathology. 
Our data suggest that uremia is not itself pro-oxidant and this feature may be driven largely by 
co-morbidity. However, it is unclear whether uremia or increased inflammation are responsible 
for the LDL lipidomic changes, or result from them. These changes in CKD patients are unlikely 
to be the consequence of lipid lowering drugs, as only 2 patients were on statin therapy and none 
was on fibrate therapy. A full understanding of the role of LDL lipidomics in CVD risk in CKD 
patients would require a prospective study with comparison of intermediate stages of CKD, as 
well as CKD with and without CVD complications. 
A limitation of the top-down lipidomic methodology is that some features in the mass 
spectra remain unidentified and it is not possible to discriminate some individual lipids within 
isomeric clusters, so further differences could be present that are not reported here. It should be 
noted that as internal standards were not used, the analysis is comparative and semi-quantitative. 
Such approaches have been reported previously (21-23) and have the advantage of avoiding the 
high expense of labeled compounds, although they do not allow the fully quantitative analysis 
that can be achieved with use of isotope-labeled internal standards (53). Finally, although, 
bootstrapping of the test data gave very good sensitivity and selectivity for discrimination, 
demonstrating the robustness of the analysis, further analysis on a validation data set would be 
desirable as the next stage of study. 
In summary, using an LC-MS approach we report the first comprehensive top-down 
lipidomic signature of LDL in kidney disease patients with normocholesterolemia. Patients with 
stage 4/5 CKD demonstrated significant changes in the lipidome of their LDL compared to age-
matched controls, and multivariant analysis gave very good discrimination of control and disease 
samples, despite the small cohorts used  (n=10). These findings illustrate the point that although 
the clinical biochemistry parameters may not appear abnormal, there may be important 
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underlying lipidomic changes that contribute to disease pathology. The lipidomic profile of CKD 
LDL offers potential for new biomarkers and novel insights into lipid metabolism and 
cardiovascular risk in this disease. Further work with early disease stages is now warranted to 
enable the relationship of these lipids with disease severity and cardiovascular events to be 
correlated. 
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Figure Legends 
 
Figure 1. Typical normal-phase LC-MS chromatograms of normolipidemic LDL lipid extract 
(Control, top) and LDL extract from CKD patients (Disease, bottom) in positive (+ve, left) and 
negative (-ve, right) ion mode. Lipid extracts were prepared according to the Folch method and 
chromatograms were normalized to relative intensity (%). Labelled peaks are triacylglycerides 
and cholesteryl esters (TAG+CE), phosphatidylinositols (PI), phosphatidylethanolamines (PE), 
phosphatidylcholines (PC) and sphingomyelins (SM). The insets depict a zoomed region for the 
elution of cholesterol sulphate (CS), N-acyltaurines (NAT), ceramides (Cer) and fatty acids (FA) 
in negative ion mode. 
 
Figure 2. Box plots showing changes in major lipids in the disease group (n=10) against the age-
matched control group (n=10). Samples were analysed in triplicate (n=3) and statistical analysis 
was carried out using the Mann-Whitney test to estimate the P values. Differences were 
considered statistically significant at p<0.05. Plots are a) total lipids detected; b) 
triacylglycerides; c) total phosphatidylcholine; d) ratio of plasmenyl ethanolamine to total 
phosphatidyl-ethanolamine; e) total lyso-phosphatidylcholine and lyso-
phosphatidylethanolamine; f) ratio of lyso-phosphatidylcholine to lyso-
phosphatidylethanolamine. 
Figure 3. Box plots of minor lipids that showed significant change in disease. Samples from the 
disease group (n=10) and the age-matched control group (n=10) were analysed in triplicate and 
statistical analysis was carried out using the Mann-Whitney test to estimate the p values. 
Differences were considered statistically significant at p<0.05. The plots are a) ceramides; b) N-
acyltaurines; c) cholesteryl sulphate; d) sulfatides. 
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Figure 4. PLSDA scores plot for merged data (lipids detected in positive and negative ion 
mode). Numbers adjacent to the symbols are patient sample codes. 
 
Figure 5. Boxplots of 2 individual lipid species that were altered in positive (PC) and negative 
ion mode (PE). Samples from the CKD group (n=10) and age-matched control group (n=10) 
were analysed in triplicate and statistical analysis was carried out using the Mann-Whitney test 
to estimate the p values. Differences were considered statistically significant at p<0.05. Plots are 
a) plasmenyl PC 40:7 and b) plasmenyl PE 38:7, where the numbers (C:n) correspond to the total 
number of carbon atoms: number of double bonds present in the acyl and alkyl chains (including 
the vinyl ether bond). 
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Table 1. Clinical biochemistry parameters in plasma for control subjects and chronic kidney 
disease patients. 
Clinical parameters Controls CKD* p-value 
n 10 10 - 
Age (years) 47±6 44±3 0.111 
BMI (kg/m2) 26±2 29±6 0.113 
Smokers/ex-smokers/non-smokers  0/1/9 2/2/8 - 
Systolic Blood Pressure (mm Hg) 113±12 124±10 0.049 
Diastolic Blood Pressure (mm Hg) 72±11 78±6 0.103 
Mean Arterial Pressure (mm Hg) 85±11 93±7 0.065 
Pulse Pressure (mm Hg) 42±6 46±7 0.189 
Plasma Glucose (mg/dL) 5.1±0.5 4.8±0.4 0.231 
HbA1c (% of Hb) 5.3±0.40 5.6±0.50 0.117 
Serum creatinine (mg/dL) 85±11 460±179 <0.0001 
MDRD eGFR (mL/min/1.73 m2) 91.2±14.1 14.8±5.3 <0.0001 
High sensitivity C-reactive protein 
(µg/mL) 
1.2±1.5 4.2±3.5 0.027 
IL-6 (pg/mL) 9.6±10.5 7.9±8.7 0.713 
Total Cholesterol (mg/dL) 5.1±0.8 4.5±0.8 0.130 
Triglycerides (mmol/L) 1.0±0.3 1.8±0.7 0.004 
HDL (mmol/L) 1.4±0.5 1.0±0.2 0.020 
LDL (mmol/L) 4.8±0.7 (n=9) 4.2±0.8 0.091 
OxLDL (U/l) 56±18 51±12 0.475 
LDL Vit E (µg/mg protein) 2.43±0.540 2.39±0.524 0.65 
LDL particle size (nm) 0.24±0.02 0.24±0.03 0.387 
Values are given as mean±standard deviation (±SD). Significance (p values) was calculated 
using a 2-tailed student t-test, and statistically significant differences are indicated by bold 
typeface. 
* Chronic Kidney Disease 
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Table 2. List of lipid classes and sub-classes identified in LDL using dual polarity detection in a 
high resolution mass spectrometer by manual analyte identification using the Human 
Metabolome database.  
Lipid Classes Number of 
Mol. Ions 
Identified 
Search Criteria 
  Formula Adducts searched 
and ionization mode 
Glycerolipids 72 
   Triacylglycerols (TAG) 72 CnHmNO6 ([M+NH4]
+) 
Sterols and steroids 14 
   Cholesterol (Chol) 1 CnHmO ([M+H-H2O]
+) 
 Cholesterol sulphates (CS) 4 CnHmO4S ([M-H]-) 
 Cholesteryl esters (CE) 8 CnHmNO2 ([M+NH4]+) 
 Steroid conjugates 1 CnHmOz ([M+H]+)/([M-H]-) 
Fatty acids  24 
   Free fatty acids (FA) 24 CnHmO2 ([M-H]
-) 
Sphingolipids 96 
   Sphingomyelins (SM) 41 CnHmN2O6P ([MH]
+) 
 Ceramides (Cer) 15 CnHmNO5 ([M+HCOO]-) 
 Hexosyl-Ceramides (HexCer) 8 CnHmNO8 ([M-H]-) 
 Lactosyl-Ceramides (LacCer) 5 CnHmNO13 ([M-H]-) 
 Acidic Glycosphingolipids (Sulfatides, ST) 27 CnHmNO11-13S ([M-H]-) 
Glycerophospholipids 140 
   Phosphatidylinositols (PI) 15 CnHmO13P ([M-H]
-) 
 Phosphatidylglycerols (PG) 6 CnHmO10P ([M-H]-) 
 Phosphatidylethanolamines (PE) 47 
    Diacyl-PE 15 CnHmNO8P ([M-H]-) 
  Plasmenyl-PE (pPE) 32 CnHmNO7P ([M-H]-) 
 Lyso-phosphatidylethanolamines (lyso-PE) 5 CnHmNO7P ([M-H]-) 
 Phosphatidylcholines (PC) 63 
    Diacyl-PC 41 CnHmNO8P ([MH]+) 
  Plasmenyl/plasmanyl-PC (pPC) 22 CnHmNO7P ([MH]+) 
 Lyso-phosphatidylcholines (lyso-PC) 4 CnHmNO7P ([MH]+) 
Lipid-related compounds 6 
   Prenols 1 CnHmOz ([M+H]
+)/([M-H]-) 
 N-acyltaurines (NAT) 5 CnHmNO4S ([M+H]+)/([M-H]-) 
TOTAL 352 
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Table 3. Summary of classification of plasma from CKD patients and controls using lipids 
profiles measured in either positive or negative ion modes, or the merged data set. Results for 
calibration (Cal) and cross-validation (CV) are shown. 
Data set Q2* Correct classification, %** Sensitivity‡ Specificity‡‡ 
Cal CV Cal CV Cal CV 
Lipids pos. 0.83 100 94 1 0.93 1 0.96 
Lipids neg. 0.81 100 96 1 0.96 1 0.96 
Merged data 0.79 100 98 1 0.97 1 1 
* 𝑄2 = 1 −  ∑ (𝑦𝑖−𝑦𝚤�)2𝑖
∑ (𝑦𝑖−𝑦�)2𝑖  
** Correct classification – percentage of cases assigned to correct classes 
‡ Sensitivity = True Positives/(True Positives + False Negatives) 
‡‡ Specificity = True Negative/(True Negatives + False Positives)  
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Figure 1. Typical normal-phase LC-MS chromatograms of normolipidemic LDL lipid extract 
(Control, top) and  CKD patients (Disease, bottom) in positive (+ve, left) and negative (-ve, right) 
ion mode. Lipid extracts were prepared according to the Folch method and chromatograms were 
normalized to relative intensity (%). Labelled peaks are triacyglycerides and cholesteryl esters 
(TAG+CE), phosphatidylinositols (PI), phosphatidylethanolamines (PE), phosphatidylcholines (PC) 
and sphingomyelins (SM). The insets depict a zoomed region for the elution of cholesterol sulphate 
(CS), N-acyltaurines (NAT), ceramides (Cer) and fatty acids (FA) in negative ion mode. 
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Figure 2. Box plots showing changes in major lipids in the disease group (n=10) against the age-
matched control group (n=10). Samples were analysed in triplicate (n=3) and statistical analysis was 
carried out using the Mann-Whitney test to estimate the P values. Differences were considered 
statistically significant at p<0.05. Plots are a) total lipids detected; b) triacylglycerides; c) total 
phosphatidylcholine; d) ratio of plasmenyl ethanolamine to total phosphatidyl-ethanolamine; e) 
total lyso-phosphatidylcholine and lyso-phosphatidylethanolamine; f) ratio of lyso-
phosphatidylcholine to lyso-phosphatidylethanolamine. 
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Figure 3. Box plots of minor lipids that showed 
significant change in CKD. Samples from the CKD 
group (n=10) and the age-matched control group 
(n=10) were analysed in triplicate and statistical 
analysis was carried out using the Mann-Whitney 
test to estimate the p values. Differences were 
considered statistically significant at p<0.05. The 
plots are a) ceramides; b) N-acyltaurines; c) 
cholesteryl sulphate; d) sulfatides. 
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Figure 4. PLSDA scores plot for merged data (lipids 
detected in positive and negative ion mode). 
Numbers adjacent to the symbols are patient 
sample codes. 
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Figure 5. Boxplots of 2 individual lipid species that were altered in positive (PC) and negative ion 
mode (PE). Samples from the CKD group (n=10) and age-matched control group (n=10) were 
analysed in triplicate and statistical analysis was carried out using the Mann-Whitney test to 
estimate the p values. Differences were considered statistically significant at p<0.05. Plots are a) 
plasmenyl PC 40:7 and b) plasmenyl PE 38:7, where the numbers (C:n) correspond to the total 
number of carbon atoms: number of double bonds present in the acyl and alkyl chains (including the 
vinyl ether bond).  
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Supplemental Information 
PLSDA Statistical analysis  
PLSDA is one of the most commonly used classification methods for analysis of omics data, 
especially metabolomics. It is based on the Partial Least Square regression (PLS) approach and 
consists of using standard PLS algorithm with dummy dependent y variables containing class labels. 
As our data is a two-class case, control and disease, the values of the dependent variable were given 
as 1 for one class and -1 for the other class.  PLSDA can be prone to overfit data, and so rigorous 
validation was undertaken. Optimization and validation of the PLSDA classification model and 
assessment of model quality were carried out using a cross validation and permutation test, using Q2 
as a measure of quality of the model. Cross-validation ensured that optimization and validation 
remained independent of each other. The statistical significance of the PLSDA classification model 
was assessed using a permutation test (1, 2). Permutation testing consists in changing randomly the 
order of the rows in the data set so the class labels are assigned randomly to the measurements. The 
classification model is then recalculated using this permuted data set. Permutation test considers the 
null hypothesis that a given classification model is not significant and describes noise.  If null 
hypothesis is true, there should be no difference in the value of the quality-of-fit criteria between 
original data set and permuted one.  After permuting the data and repeating calculations a sufficient 
number of times a null hypothesis (H0) distribution of the quality-of-fit criterion is obtained. For the 
results to be considered significant, the value of the quality-of-fit criterion for the original, non-
permuted data set should be outside either the 95 or 99% confidence bounds of the H0 distribution 
of the values generated from the permuted data.   
In the present study data were permuted 1000 times and Q2 was used as quality-of-fit 
criterion for the permutation test. Q2 is based on an evaluation of the error between the predicted and 
known variables, and was calculated using the following formula (38): 
𝑄2 = 1 − ∑ (𝑦𝑖−𝑦�𝑖)2𝑖
∑ (𝑦𝑖−𝑦�)2𝑖 , 
where yi is a value for the ith sample, 𝑦�𝑖is a predicted value for the i
th sample and 𝑦� is the 
mean y value.  
Selection of the lipid species contributing to the discrimination between CKD patient and 
control groups was achieved using the Variable Importance in Projection (VIP) (36), which is 
effectively the weighted sum of the squares of the weight in the PLS analysis, and allows ranking of 
the variables according to their importance in the PLS model.VIP takes into account amount of the 
variance explained by the variable for each latent variables extracted and covariance between this 
variable and dependent variable y.  
VIP of the jth variable, VIPj, for the model with K latent variables is calculated using the 
following equation: 
VIPj=�p∑ �bk2tk' tk�(wjk)2Kk=1∑ �bk2tk' tk�Kk=1 , 
where p is a total number of variables in the model, tk and bk are scores and regression coefficient 
for the kth latent variable, respectively, and wjk is a weight for the jth variable and kth latent variable.  
A VIP cut-off value of 0.85 was used for the merged set. The final classification model included 48 
species detected in the positive mode and 55 in the negative mode. 
PLSDA, permutation test and VIP algorithms were implemented in MATLAB, v. 7.12 (release 
2011a).  
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Supplemental Figure 1. Scheme showing the data processing approaches for MS 
data. The number of features identified in top-down LC-MS analysis of LDL from 
control and chronic kidney disease LDL, and  the numbers of lipids identified at 
subsequent  data processing  stages, are given. The tables and figures in which 
these data sets are presented are indicated in blue. 
1619 features  
in +ve & -ve ion 
352 lipid species 
in 18 classes 
(Table 2; Suppl Table 1) 
Manual matching  with 
databases & removal 
of adducts or 
contaminants 
48 +ve ion, 55 –ve ion  species & 58 
ions in merged dataset 
(Suppl Table 2; Figures 4 & 5, Table 3) 
PLSDA analysis  & 
optimization by VIP 
300 features in 12 classes 
(142 in +ve ion & 158 in –ve) 
(Figures 2 & 3) 
Automated filtering by 
XCMS & analysis 
Raw MS data 
in mzMXL 
Feature 
detection with 
XCMS platform 
Supplemental Table 1. List of ions observed in the averaged mass spectra (LC-MS) for each of the 
different lipid classes composing LDL population detected with polarity switching. The corresponding 
molecular formulae and proposed identifications of the lipid species are given, based on a mass error of 
<5 ppm between the experimental accurate mass and the calculated monoisotopic mass from the 
theoretical formula obtained using a home-built database and the Human Metabolome Project (HMDB). 
The m/z values used in this analysis were manual peak-top measurements, and may differ fractionally 
from the values quoted in Supplemental Table 2, which are mean m/z values from the automated 
extraction of features detected in at least 50% of data files, with error <2.5ppm and with 5s of retention 
time deviation. “d” indicates diacyl phospholipids and “p” indicates plasmanyl / plasmenyl phospholipids. 
 
Lipid sub-classes Molecular ions 
Analysed m/z 
Molecular 
Formula 
Tentative 
Lipid ID 
Calculated 
Monoisotopic 
mass 
Discrepancy 
(ppm) 
Triacylglycerides (TAG)      
([M+NH4]+) 780.7076 C48H94NO6 45:1 780.7081 0.7 
 782.7230 C48H96NO6 45:0 782.7238 1.0 
 792.7075 C49H94NO6 46:2 792.7081 0.8 
 794.7230 C49H96NO6 46:1 794.7238 1.0 
 796.7396 C49H98NO6 46:0 796.7394 0.2 
 806.7241 C50H96NO6 47:2 806.7238 0.4 
 808.7386 C50H98NO6 47:1 808.7394 1.0 
 816.7079 C51H94NO6 48:4 816.7081 0.3 
 818.7234 C51H96NO6 48:3 818.7238 0.4 
 820.7382 C51H98NO6 48:2 820.7394 1.5 
 822.7543 C51H100NO6 48:1 822.7551 0.9 
 824.7708 C51H102NO6 48:0 824.7707 0.1 
 832.7392 C52H98NO6 49:3 832.7394 0.3 
 834.7538 C52H100NO6 49:2 834.7551 1.5 
 836.7705 C52H102NO6 49:1 836.7707 0.3 
 838.7861 C52H104NO6 49:0 838.7864 0.3 
 840.7083 C53H94NO6 50:6 840.7081 0.2 
 842.7238 C53H96NO6 50:5 842.7238 0.0 
 844.7392 C53H98NO6 50:4 844.7394 0.3 
 846.7545 C53H100NO6 50:3 846.7551 0.7 
 848.7696 C53H102NO6 50:2 848.7707 1.3 
 850.7863 C53H104NO6 50:1 850.7864 0.1 
 858.7540 C54H100NO6 51:4 858.7551 1.2 
 860.7701 C54H102NO6 51:3 860.7707 0.7 
 862.7848 C54H104NO6 51:2 862.7864 1.8 
 864.8020 C54H106NO6 51:1 864.802 0.0 
 866.7239 C55H96NO6 52:7 866.7238 0.2 
 868.7389 C55H98NO6 52:6 868.7394 0.6 
 870.7559 C55H100NO6 52:5 870.7551 1.0 
 872.7696 C55H102NO6 52:4 872.7707 1.3 
 874.7850 C55H104NO6 52:3 874.7864 1.6 
 876.7989 C55H106NO6 52:2 876.802 3.6 
 886.7846 C56H104NO6 53:4 886.7864 2.0 
 888.8011 C56H106NO6 53:3 888.802 1.0 
 890.7227 C57H96NO6 54:9 890.7238 1.2 
 890.8172 C56H108NO6 53:2 890.8177 0.5 
 892.7387 C57H98NO6 54:8 892.7394 0.8 
 894.7546 C57H100NO6 54:7 894.7551 0.5 
 896.7697 C57H102NO6 54:6 896.7707 1.1 
 898.7848 C57H104NO6 54:5 898.7864 1.7 
 900.8005 C57H106NO6 54:4 900.802 1.7 
 902.8173 C57H108NO6 54:3 902.8177 0.4 
 904.8325 C57H110NO6 54:2 904.8333 0.9 
 910.7844 C58H104NO6 55:8 910.7864 2.2 
 914.7239 C59H96NO6 56:11 914.7238 0.1 
 914.8156 C58H108NO6 55:4 914.8177 2.3 
 916.7394 C59H98NO6 56:10 916.7394 0.0 
 918.7544 C59H100NO6 56:9 918.7551 0.7 
 920.7700 C59H102NO6 56:8 920.7707 0.8 
 922.7848 C59H104NO6 56:7 922.7864 1.7 
 924.8010 C59H106NO6 56:6 924.802 1.1 
 926.8163 C59H108NO6 56:5 926.8177 1.5 
 928.8315 C59H110NO6 56:4 928.8333 2.0 
 930.8481 C59H112NO6 56:3 930.849 0.9 
 932.8620 C59H114NO6 56:2 932.8646 2.8 
 940.7394 C61H98NO6 58:12 940.7394 0.0 
 942.7545 C61H100NO6 58:11 942.7551 0.6 
 944.7698 C61H102NO6 58:10 944.7707 1.0 
 946.7851 C61H104NO6 58:9 946.7864 1.3 
 948.8004 C61H106NO6 58:8 948.802 1.7 
 950.8160 C61H108NO6 58:7 950.8177 1.8 
 952.8316 C61H110NO6 58:6 952.8333 1.8 
 954.8469 C61H112NO6 58:5 954.849 2.2 
 956.8622 C61H114NO6 58:4 956.8646 2.5 
 958.8788 C61H116NO6 58:3 958.8803 1.5 
 966.7548 C63H100NO6 60:13 966.7551 0.3 
 968.7703 C63H102NO6 60:12 968.7707 0.4 
 970.7851 C63H104NO6 60:11 970.7864 1.3 
 972.8011 C63H106NO6 60:10 972.802 0.9 
 990.7553 C65H100NO6 62:15 990.7551 0.2 
 992.7706 C65H102NO6 62:14 992.7707 0.1 
 994.7852 C65H104NO6 62:13 994.7864 1.2 
Cholesteryl Esters (CE)      
([M+NH4]+) 640.6039 C43H78NO2 16:1 640.6033 1.0 
 642.6180 C43H80NO2 16:0 642.6189 1.4 
 666.6179 C45H80NO2 18:2 666.6189 1.5 
 668.6346 C45H82NO2 18:1 668.6346 0.1 
 688.6022 C47H78NO2 20:5 688.6033 1.5 
 690.6181 C47H80NO2 20:4 690.6189 1.2 
 692.6376 C47H82NO2 20:3 692.6346 4.4 
 714.6182 C49H80NO2 22:6 714.6189 1.0 
Phosphatidylcholines 
(PC)* 
     
([MH]+) 704.5239 C38H75NO8P dPC/30:1 704.5230 1.2 
 706.5385 C38H77NO8P dPC/30:0 706.5387 0.3 
 718.5751 C40H81NO7P pPC/32:1 718.5751 0.0 
 720.5543 C39H79NO8P dPC/31:0 720.5543 0.0 
 720.5909 C40H83NO7P pPC/32:0 720.5907 0.3 
 730.5381 C40H77NO8P dPC/32:2 730.5387 0.8 
 732.5532 C40H79NO8P dPC/32:1 732.5543 1.5 
 734.5696 C40H81NO8P dPC/32:0 734.5700 0.5 
 742.5743 C42H81NO7P pPC/34:3 742.5751 1.0 
 744.5536 C41H79NO8P dPC/33:2 744.5543 1.0 
 744.5910 C42H83NO7P pPC/34:2 744.5907 0.4 
 746.5691 C41H81NO8P dPC/33:1 746.5700 1.2 
 746.6065 C42H85NO7P pPC/34:1 746.6064 0.2 
 748.5864 C41H83NO8P dPC/33:0 748.5856 1.0 
 754.5381 C42H77NO8P dPC/34:4 754.5387 0.8 
 756.5546 C42H79NO8P dPC/34:3 756.5543 0.4 
 758.5685 C42H81NO8P dPC/34:2 758.57 2.0 
 760.5851 C42H83NO8P dPC/34:1 760.5856 0.7 
 762.6014 C42H85NO8P dPC/34:0 762.6013 0.2 
 764.5617 C44H79NO7P pPC/36:6 764.5594 3.0 
 766.5744 C44H81NO7P pPC/36:5 766.5751 0.9 
 768.5904 C44H83NO7P pPC/36:4 768.5907 0.4 
 770.6052 C44H85NO7P pPC/36:3 770.6064 1.5 
 772.5842 C43H83NO8P dPC/35:2 772.5856 1.9 
 772.6216 C44H87NO7P pPC/36:2 772.622 0.5 
 774.5995 C43H85NO8P dPC/35:1 774.6013 2.3 
 778.5364 C44H77NO8P dPC/36:6 778.5387 2.9 
 780.5536 C44H79NO8P dPC/36:5 780.5543 0.9 
 782.5693 C44H81NO8P dPC/36:4 782.57 0.9 
 784.5844 C44H83NO8P dPC/36:3 784.5856 1.6 
 786.5989 C44H85NO8P dPC/36:2 786.6013 3.0 
 788.6154 C44H87NO8P dPC/36:1 788.6169 1.9 
 790.5753 C46H81NO7P pPC/38:7 790.5751 0.3 
 792.5547 C45H79NO8P dPC/37:6 792.5543 0.5 
 792.5911 C46H83NO7P pPC/38:6 792.5907 0.5 
 794.6056 C46H85NO7P pPC/38:5 794.6064 1.0 
 796.5848 C45H83NO8P dPC/37:4 796.5856 1.0 
 796.6214 C46H87NO7P pPC/38:4 796.622 0.8 
 798.6375 C46H89NO7P pPC/38:3 798.6377 0.2 
 800.6149 C45H87NO8P dPC/37:2 800.6169 2.5 
 802.5383 C46H77NO8P dPC/38:8 802.5387 0.5 
 804.5541 C46H79NO8P dPC/38:7 804.5543 0.3 
 806.5696 C46H81NO8P dPC/38:6 806.57 0.5 
 808.5849 C46H83NO8P dPC/38:5 808.5856 0.9 
 810.5994 C46H85NO8P dPC/38:4 810.6013 2.3 
 812.6160 C46H87NO8P dPC/38:3 812.6169 1.1 
 814.6310 C46H89NO8P dPC/38:2 814.6326 1.9 
 816.5912 C48H83NO7P pPC/40:8 816.5907 0.6 
 818.6069 C48H85NO7P pPC/40:7 818.6064 0.7 
 820.5853 C47H83NO8P dPC/39:6 820.5856 0.4 
 820.6214 C48H87NO7P pPC/40:6 820.6220 0.8 
 822.5656 C46H81NO9P dPC/38:6-OH 822.5649 0.9 
 822.6372 C48H89NO7P pPC/40:5 822.6377 0.6 
 828.5520 C48H79NO8P dPC/40:9 828.5543 2.8 
 830.5707 C48H81NO8P dPC/40:8 830.5700 0.9 
 832.5858 C48H83NO8P dPC/40:7 832.5856 0.2 
 834.6025 C48H85NO8P dPC/40:6 834.6013 1.5 
 836.6159 C48H87NO8P dPC/40:5 836.6169 1.2 
 838.6317 C48H89NO8P dPC/40:4 838.6326 1.0 
 846.6376 C50H89NO7P pPC/42:6 846.6377 0.1 
 848.6529 C50H91NO7P pPC/42:5 848.6533 0.5 
 850.6684 C50H93NO7P pPC/42:4 850.6690 0.7 
 856.5851 C50H83NO8P dPC/42:9 856.5856 0.6 
Lyso-
phosphatidylcholines 
(Lyso-PC) 
     
([MH]+) 496.3403 C24H51NO7P 16:0 496.3403 0.0 
 520.3408 C26H51NO7P 18:2 520.3403 0.9 
 522.3561 C26H53NO7P 18:1 522.3560 0.3 
 524.3718 C26H55NO7P 18:0 524.3716 0.4 
Sphingomyelins 
(SM)** 
     
([MH]+) 647.5128 C35H72N2O6P 30:1 647.5128 0.0 
 661.5283 C36H74N2O6P 31:1 661.5284 0.2 
 673.5287 C37H74N2O6P 32:2 673.5284 0.4 
 675.5431 C37H76N2O6P 32:1 675.5441 1.5 
 689.5598 C38H78N2O6P 33:2 689.5597 0.1 
 691.5758 C38H80N2O6P 33:1 691.5754 0.6 
 701.5598 C39H78N2O6P 34:2 701.5597 0.1 
 703.5738 C39H80N2O6P 34:1 703.5754 2.3 
 705.5909 C39H82N2O6P 34:1 705.5910 0.2 
 715.5750 C40H80N2O6P 35:2 715.5754 0.6 
 717.5905 C40H82N2O6P 35:1 717.5910 0.8 
 719.5707 C39H80N2O7P 34:1-OH 719.5703 0.5 
 725.5570 C41H78N2O6P 36:4 725.5597 3.8 
 727.5742 C41H80N2O6P 36:3 727.5754 1.6 
 729.5911 C41H82N2O6P 36:2 729.5910 0.1 
 731.6053 C41H84N2O6P 36:1 731.6067 1.9 
 733.6220 C41H86N2O6P 36:0 733.6224 0.5 
 743.6063 C42H84N2O6P 37:0 743.6067 0.5 
 745.6219 C42H86N2O6P 37:1 745.6224 0.6 
 753.5886 C43H82N2O6P 38:4 753.5910 3.3 
 755.6064 C43H84N2O6P 38:3 755.6067 0.4 
 757.6223 C43H86N2O6P 38:2 757.6224 0.1 
 759.6383 C43H88N2O6P 38:1 759.6380 0.4 
 771.6379 C44H88N2O6P 39:2 771.6380 0.1 
 773.6538 C44H90N2O6P 39:1 773.6537 0.2 
 779.6037 C45H84N2O6P 40:5 779.6067 3.8 
 781.6202 C45H86N2O6P 40:4 781.6224 2.8 
 783.6381 C45H88N2O6P 40:3 783.6380 0.1 
 785.6539 C45H90N2O6P 40:2 785.6537 0.3 
 787.6678 C45H92N2O6P 40:1 787.6693 1.9 
 797.6537 C46H90N2O6P 41:3 797.6537 0.1 
 799.6690 C46H92N2O6P 41:2 799.6693 0.4 
 801.6846 C46H94N2O6P 41:1 801.6850 0.4 
 811.6691 C47H92N2O6P 42:3 811.6693 0.2 
 813.6832 C47H94N2O6P 42:2 813.6850 2.2 
 815.7000 C47H96N2O6P 42:1 815.7006 0.7 
 825.6850 C48H94N2O6P 43:3 825.6850 0.1 
 827.6995 C48H96N2O6P 43:2 827.7006 1.3 
 833.6512 C49H90N2O6P 44:5 833.6537 2.9 
 835.6658 C49H92N2O6P 44:4 835.6693 4.2 
 839.7008 C49H96N2O6P 44:3 839.7006 0.2 
Ceramides (Cer)**      
([M+HCOO]-) 582.5100 C35H68NO5 34:1 582.5097 0.4 
 610.5413 C37H72NO5 36:1 610.5410 0.4 
 638.5725 C39H76NO5 38:1 638.5723 0.2 
 652.5893 C40H78NO5 39:1 652.5880 2.0 
 664.5880 C41H78NO5 40:2 664.5880 0.0 
 666.6037 C41H80NO5 40:1 666.6036 0.1 
 678.6034 C42H80NO5 41:2 678.6036 0.4 
 680.6190 C42H82NO5 41:1 680.6193 0.4 
 692.6190 C43H82NO5 42:2 692.6193 0.4 
 694.6345 C43H84NO5 42:1 694.6349 0.6 
 706.6346 C44H84NO5 43:1 706.6349 0.5 
 708.6506 C44H86NO5 43:1 708.6506 0.0 
 710.6311 C43H84NO6 42:1-OH 710.6299 1.7 
 720.6504 C45H86NO5 44:2 720.6506 0.3 
 722.6651 C45H88NO5 44:1 722.6662 1.6 
HexosylCeramide**      
([M+HCOO]-) 744.5623 C41H78NO10 34:1 744.5626 0.4 
 826.6404 C47H88NO10 40:2 826.6408 0.5 
 828.6559 C47H90NO10 40:1 828.6565 0.7 
 840.6564 C48H90NO10 41:2 840.6565 0.1 
 842.6718 C48H92NO10 41:1 842.6721 0.4 
 854.6719 C49H92NO10 42:2 854.6721 0.3 
 856.6874 C49H94NO10 42:1 856.6878 0.4 
 868.6874 C50H94NO10 43:2 868.6878 0.4 
LactosylCeramides**      
([M-H]-) 832.5779 C44H82NO13 32:1 832.5786 0.9 
 858.5935 C46H84NO13 34:2 858.5943 0.9 
 860.6090 C46H86NO13 34:1 860.6099 1.1 
 886.6249 C48H88NO13 36:2 886.6256 0.8 
 970.7190 C54H100NO13 42:2 970.7195 0.5 
Sulfatides (ST)**      
([M-H]-) 750.4828 C38H72NO11S 32:1 750.4826 0.3 
 764.4977 C39H74NO11S 33:1 764.4983 0.7 
 766.4771 C38H72NO12S 32:1-OH 766.4775 0.6 
 776.4979 C40H74NO11S 34:1 776.4983 0.5 
 778.5134 C40H76NO11S 34:0 778.5139 0.7 
 792.4926 C40H74NO12S 34:1-OH 792.4932 0.7 
 794.5084 C40H76NO12S 34:0-OH 794.5088 0.5 
 812.5189 C40H78NO13S - 812.5194 0.6 
 832.5598 C44H82NO11S 38:2 832.5609 1.3 
 834.5763 C44H84NO11S 38:1 834.5765 0.2 
 850.5721 C44H84NO12S 38:1-OH 850.5714 0.8 
 860.5922 C46H86NO11S 40:2 860.5922 0.0 
 862.6085 C46H88NO11S 40:1 862.6078 0.8 
 874.6069 C47H88NO11S 41:1 874.6078 1.0 
 876.5873 C46H86NO12S 40:2-OH 876.5871 0.3 
 878.6031 C46H88NO12S 40:1-OH 878.6027 0.4 
 886.6074 C48H88NO11S 42:3 886.6078 0.5 
 888.6233 C48H90NO11S 42:2 888.6235 0.2 
 892.6179 C47H90NO12S 41:0-OH 892.6184 0.5 
 896.6132 C46H90NO13S 40:0-(OH)2 896.6133 0.1 
 902.6030 C48H88NO12S 42:3-OH 902.6027 0.3 
 904.6180 C48H90NO12S 42:2-OH 904.6184 0.4 
 906.6342 C48H92NO12S 42:1-OH 906.6340 0.2 
 920.6136 C48H90NO13S 42:2-(OH)2 920.6133 0.3 
 922.6289 C48H92NO13S 42:1-(OH)2 922.6289 0.0 
 932.6473 C50H94NO12S 44:2-OH 932.6497 2.5 
 1010.5651 C56H84NO13S - 1010.5663 1.2 
Free Fatty Acids (FA) 
and conjugates 
     
([M-H]-) 227.2017 C14H27O2 14:0 227.2011 2.6 
 241.2174 C15H29O2 15:0 241.2168 2.7 
 253.2173 C16H29O2 16:1 253.2168 2.2 
 255.2328 C16H31O2 16:0 255.2324 1.5 
 267.2329 C17H31O2 17:1 267.2324 1.9 
 269.2486 C17H33O2 17:0 269.2481 2.0 
 277.2173 C18H29O2 18:3 277.2168 2.0 
 279.2330 C18H31O2 18:2 279.2324 2.1 
 281.2486 C18H33O2 18:1 281.2481 1.9 
 283.2640 C18H35O2 18:0 283.2637 1.0 
 297.2434 C18H33O3 18:1-OH 297.2430 1.4 
 303.2329 C20H31O2 20:4 303.2324 1.6 
 305.2489 C20H33O2 20:3 305.2481 2.8 
 307.2646 C20H35O2 20:2 307.2637 2.9 
 319.2278 C20H31O3 20:4-OH 319.2273 1.5 
 327.2330 C22H31O2 22:6 327.2324 1.8 
 331.2643 C22H35O2 22:4 331.2637 1.8 
 367.3581 C24H47O2 24:0 367.3576 1.3 
 369.3010 C22H41O4 22:1-OH 369.3005 1.4 
 381.3739 C25H49O2 25:0 381.3733 1.7 
 395.3893 C26H51O2 26:0 395.3889 1.0 
 409.4051 C27H53O2 27:0 409.4046 1.3 
 423.4208 C28H55O2 28:0 423.4202 1.4 
 449.3630 C28H49O4 28:3-OH 449.3631 0.2 
Phosphatidylinositols 
(PI) 
     
([M-H]-) 807.5018 C41H76O13P 32:1 807.5024 0.7 
 809.5166 C41H7O13P 32:0 809.5180 1.7 
 833.5175 C43H78O13P 34:2 833.5180 0.6 
 835.5333 C43H80O13P 34:1 835.5337 0.4 
 847.5692 C45H84O12P 35:2 847.5700 1.0 
 857.5180 C45H78O13P 36:4 857.5180 0.0 
 859.5334 C45H80O13P 36:3 859.5337 0.3 
 861.5490 C45H82O13P 36:2 861.5493 0.4 
 863.5644 C45H84O13P 36:1 863.5650 0.6 
 871.5320 C46H80O13P 37:4 871.5337 1.9 
 881.5187 C47H78O13P 38:6 881.5180 0.8 
 883.5332 C47H80O13P 38:5 883.5337 0.5 
 885.5489 C47H82O13P 38:4 885.5493 0.5 
 909.5486 C49H82O13P 40:6 909.5493 0.8 
 911.5642 C49H84O13P 40:5 911.5650 0.8 
Phosphatidyl-
ethanolamines (PE)* 
     
([M-H]-) 698.5125 C39H73NO7P pPE/34:3 698.5125 0.0 
 700.5282 C39H75NO7P pPE/34:2 700.5281 0.1 
 702.5436 C39H77NO7P pPE/34:1 702.5438 0.2 
 712.5284 C40H75NO7P pPE/35:3 712.5281 0.4 
 714.5074 C39H73NO8P dPE/34:2 714.5074 0.0 
 716.5237 C39H75NO8P dPE/34:1 716.5230 0.9 
 720.4967 C41H71NO7P pPE/36:6 720.4968 0.2 
 722.5121 C41H73NO7P pPE/36:5 722.5125 0.5 
 724.5280 C41H75NO7P pPE/36:4 724.5281 0.2 
 726.5440 C41H77NO7P pPE/36:3 726.5438 0.3 
 728.5593 C41H79NO7P pPE/36:2 728.5594 0.2 
 730.5753 C41H81NO7P pPE/36:1 730.5751 0.3 
 732.4960 C42H71NO7P pPE/37:7 732.4968 1.1 
 734.5123 C42H73NO7P pPE/37:6 734.5125 0.2 
 736.4918 C41H71NO8P dPE/36:5 736.4917 0.1 
 736.5280 C42H75NO7P pPE/37:5 736.5281 0.2 
 738.5072 C41H73NO8P dPE/36:4 738.5074 0.2 
 740.5230 C41H75NO8P dPE/36:3 740.5230 0.0 
 742.5385 C41H77NO8P dPE/36:2 742.5387 0.2 
 744.4969 C43H71NO7P pPE/38:8 744.4968 0.1 
 744.5547 C41H79NO8P dPE/36:1 744.5543 0.5 
 746.5121 C43H73NO7P pPE/38:7 746.5125 0.5 
 748.5271 C43H75NO7P pPE/38:6 748.5281 1.4 
 750.5421 C43H77NO7P pPE/38:5 750.5438 2.2 
 752.5592 C43H79NO7P pPE/38:4 752.5594 0.3 
 756.5908 C43H83NO7P pPE/38:3 756.5907 0.1 
 760.5270 C44H75NO7P pPE/39:6 760.5281 1.5 
 762.5066 C43H73NO8P dPE/38:6 762.5074 1.0 
 764.5225 C43H75NO8P dPE/38:5 764.5230 0.7 
 766.5383 C43H77NO8P dPE/38:4 766.5387 0.5 
 768.5543 C43H79NO8P dPE/38:3 768.5543 0.0 
 772.5269 C45H75NO7P pPE/40:8 772.5281 1.6 
 774.5424 C45H77NO7P pPE/40:7 774.5438 1.8 
 776.5590 C45H79NO7P pPE/40:6 776.5594 0.5 
 778.5746 C45H81NO7P pPE/40:5 778.5751 0.6 
 780.5908 C45H83NO7P pPE/40:4 780.5907 0.1 
 782.6067 C45H85NO7P pPE/40:3 782.6064 0.4 
 788.5220 C45H75NO8P dPE/40:7 788.5230 1.3 
 790.5377 C45H77NO8P dPE/40:6 790.5387 1.2 
 792.5537 C45H79NO8P dPE/40:5 792.5543 0.8 
 800.5583 C47H79NO7P pPE/42:8 800.5594 1.4 
 802.5741 C47H81NO7P pPE/42:7 802.5751 1.2 
 808.6212 C47H87NO7P pPE/42:4 808.6220 1.0 
 826.5744 C49H81NO7P pPE/44:8 826.5751 0.8 
 828.5902 C49H83NO7P pPE/44:7 828.5907 0.6 
 830.6055 C49H85NO7P pPE/44:6 830.6064 1.0 
 832.6214 C49H87NO7P pPE/44:5 832.6220 0.7 
Lyso-
phosphatidylethanola
mines (lyso-PE) 
     
([M-H]-) 452.2792 C21H43NO7P 16:0 452.2777 3.3 
 464.3144 C23H47NO6P p18:0 464.3141 0.6 
 476.2783 C23H43NO7P 18:2 476.2777 1.2 
 478.2935 C23H45NO7P 18:1 478.2934 0.3 
 480.3094 C23H47NO7P 18:0 480.3090 0.8 
Phosphatidylglycerol 
(PG) 
     
([M-H]-) 743.4851 C40H72O10P 34:3 743.4863 1.6 
 745.5018 C40H74O10P 34:2 745.5020 0.2 
 747.5179 C40H76O10P 34:1 747.5176 0.4 
 771.5167 C42H76O10P 36:3 771.5176 1.2 
 773.5325 C42H78O10P 36:2 773.5333 1.0 
 775.5483 C42H80O10P 36:1 775.5489 0.8 
Sterols and Steroid 
derivatives 
     
([M-H2O+H]+) 369.3516 C27H45 n/a 369.3521 1.4 
([M-H]-) 409.3106 C28H41O2  409.3107 0.1 
      
Cholesterol sulphates 
([M-H]-) 
465.3041 C27H45O4S  
465.3039 0.5 
 479.3199 C28H47O4S  479.3195 0.8 
 493.3357 C29H49O4S  493.3352 1.1 
 507.3515 C30H51O4S  507.3508 1.4 
Other lipid-like 
compounds 
     
([M+HCOO]-) 395.2437 C22H35O6  395.2434 0.9 
Lipoamino acids  
(N-acyltaurines)  
     
([M-H]-) 376.2528 C19H38NO4S 16:0 376.2522 1.7 
 390.2682 C20H40NO4S 18:0 390.2678 1.0 
 400.2526 C21H38NO4S 18:2 400.2522 1.1 
 402.2679 C21H40NO4S 18:1 402.2678 0.2 
 430.2995 C23H44NO4S 20:0 430.2991 0.9 
a The structures (C:n) are proposed based on the total number of carbons that compose the fatty acyl chains 
and the total number of double bonds that may be considered for the m/z value observed. 
* Plasmalogen phospholipid species may contain the contribution of alkyl- or alkenyl-acyl. 
** Compounds may contain the contribution of sphin-4-enine or sphinganine structure. 
 
Supplemental Table 2.  Identification of lipid species that were found to be discriminating for CKD 
using PLSDA. A final cut-off of 0.85 for the significance factor was used. Rt med and m/z med 
correspond to the averaged retention time and mass-to-charge ratio  of an identified feature from 
all chromatographic runs in which the feature was identified. The lipid species were identified by 
matching the experimental m/z to the calculated monoisotopic mass to within 5 ppm mass accuracy. 
The m/z values quoted in this table are mean m/z values from the automated extraction of features, 
and hence may differ fractionally from the manual peak-top m/z values quoted in Supplemental 
Table 1. “d” indicates diacyl phospholipids and “p” indicates plasmanyl / plasmenyl phospholipids. 
Lipids in Positive Ion Mode 
Lipid Class Chain length: 
double bonds 
m/z med Rt med Significance 
parameter 
pPC 36:6 764.5601 19.539 1.47 
dPC 36:5 780.5551 19.579 1.45 
dPC 37:4 796.5862 19.589 1.38 
dPC 32:1 732.5549 20.083 1.36 
TAG 52:4 872.7706 2.532 1.32 
SM 36:1 731.6062 21.065 1.27 
TAG 52:3 874.7861 2.579 1.25 
SM 39:1 773.6537 21.059 1.23 
dPC 38:6 806.5703 19.507 1.22 
TAG 54:4 900.8015 2.564 1.19 
dPC 39:6 820.5851 19.492 1.18 
dPC 40:6 834.6006 19.488 1.14 
TAG 54:3 902.8172 2.626 1.13 
pPC 38:7 790.5761 19.472 1.11 
dPC 38:4 810.6004 19.577 1.11 
dPC 34:3 756.5552 19.901 1.11 
pPC 40:7 818.6061 19.554 1.09 
dPC 36:6 778.5388 19.573 1.05 
dPC 36:5 780.5518 19.975 1.05 
TAG 54:5 898.7860 2.532 1.05 
TAG 58:8 948.8015 2.510 1.05 
SM 42:3 811.6693 20.885 1.03 
pPC 42:5 848.6522 19.782 1.03 
TAG 56:7 922.7866 2.978 1.02 
dPC 38:8 802.5370 19.578 1.02 
dPC 36:0 790.6231 20.081 1.00 
dPC 40:0 828.5513 19.506 1.00 
TAG 55:4 914.7815 2.509 0.99 
dPC 38:5 808.5836 19.536 0.97 
SM 35:1 717.5906 21.085 0.97 
TAG 58:9 846.7552 2.535 0.97 
dPC 32:2 730.5393 20.038 0.95 
dPC 33:1 746.5715 20.063 0.94 
dPC 36:1 788.6115 20.039 0.92 
dPC 38:3 812.6077 19.576 0.92 
SM 36:3 727.5631 21.123 0.91 
dPC 30:1 704.5242 20.127 0.91 
SM 38:2 757.6225 20.938 0.91 
SM 38:1 759.6377 21.050 0.90 
SM 38:0 761.6439 21.047 0.90 
TAG 52:6 870.7554 2.510 0.89 
TAG 55:3 916.7966 2.509 0.88 
TAG 58:7 950.8161 2.529 0.88 
PC / 708.5452 20.255 0.87 
SM 36:0 733.6126 21.055 0.87 
TAG 52:1 878.8094 2.642 0.87 
SM 36:2 729.5910 20.984 0.87 
dPC 40:8 830.5681 19.507 0.86 
 
Lipids in Negative Ion Mode 
Lipid Class Chain length: 
double bonds 
m/z med Rt med Significance 
parameter 
dPC 32:1 776.5450 21.178 1.78 
Cer / 698.6227 2.821 1.51 
pPE 36:6 720.4984 13.133 1.50 
dPC 36:5 824.5448 20.684 1.48 
dPC 36:6 822.5294 20.643 1.45 
dPE 34:2 714.5093 13.647 1.28 
dPC 34:4 798.5285 20.775 1.24 
pPE 38:7 746.5137 13.032 1.23 
dPE 36:3 740.5247 13.512 1.16 
dPE 34:1 716.5259 13.687 1.15 
SM 36:2 773.5816 22.011 1.14 
dPE 38:4 752.5509 13.086 1.13 
dPC 34:0 806.5823 21.158 1.13 
dPC 34:1 804.5748 21.145 1.12 
dPE 36:4 738.5090 13.275 1.12 
SM 42:3 855.6594 21.880 1.11 
SM 41:3 841.6440 21.866 1.11 
dPC 38:5 852.5750 20.720 1.10 
PC 40:6 878.5913 20.545 1.09 
PC 38:7 848.5447 20.538 1.09 
pPE 40:7 774.5451 12.965 1.08 
SM 36:1 775.5968 22.085 1.07 
SM 34:1 749.5820 21.968 1.07 
dPC 38:6 850.5600 20.583 1.05 
HexCer 43:0 872.6835 3.011 1.04 
pPC 36:3 814.5966 21.210 1.04 
Cer 41:2 678.6050 2.831 1.04 
pPE 38:5 750.5450 13.090 1.03 
dPC 36:4 826.5600 20.717 1.02 
Cer 44:1 722.6675 2.817 1.01 
dPE 36:2 742.5404 13.576 1.00 
dPC 38:6 750.5295 21.341 1.00 
dPC 40:5 790.5971 21.508 1.00 
dPC 32:2 774.5295 21.109 1.00 
HexCer 41:1 842.6727 3.041 1.00 
dPE 38:5 764.5246 13.146 0.97 
dPC 30:3 744.5555 21.133 0.97 
SM 30:2 689.5519 22.129 0.97 
dPE 38:3 768.5461 13.193 0.97 
dPC 34:3 800.5448 20.985 0.97 
Cer 40:2 664.5893 2.833 0.94 
Cer 34:1 582.5108 2.874 0.92 
HexCer 42:2 854.6725 3.029 0.92 
Cer 42:1 694.6359 2.822 0.92 
dPE 38:6 762.5085 13.157 0.91 
SM 30:1 691.5037 22.254 0.90 
dPE 38:4 766.5399 13.203 0.89 
pPE 40:8 772.5293 12.917 0.89 
pPE 36:5 722.5139 13.146 0.88 
dPC 38:3 856.5981 20.665 0.87 
Cer 41:1 680.6205 2.825 0.87 
SM 37:1 789.6124 22.086 0.87 
SM 38:1 803.6284 22.067 0.86 
dPC 28:0 722.4984 21.359 0.85 
SM 34:1 749.5720 22.139 0.84 
 
Merged data set - Positive and Negative Ion Modes 
Lipid Class Chain length: 
double bonds 
m/z med Rt med Significance 
parameter 
dPC 32:1 776.5450 21.178 1.38 
pPC 36:6 764.5601 19.539 1.33 
dPC 36:5 780.5551 19.579 1.31 
TAG 52:4 872.7706 2.532 1.29 
pPE 36:6 720.4984 13.133 1.24 
PC 32:1 732.5549 20.083 1.22 
TAG 52:3 874.7861 2.579 1.21 
Cer / 698.6227 2.821 1.20 
TAG 54:4 900.8015 2.564 1.18 
dPC 36:6 822.5294 20.643 1.13 
dPC 37:4 796.5862 19.589 1.13 
SM 36:1 731.6062 21.065 1.10 
dPC 36:5 824.5448 20.684 1.10 
dPE 38:4 752.5509 13.086 1.08 
pPE 38:7 746.5137 13.032 1.07 
TAG 54:5 898.7860 2.532 1.07 
dPC 38:6 806.5703 19.507 1.07 
dPC 39:6 820.5851 19.492 1.07 
dPC 40:6 834.6006 19.488 1.05 
TAG 54:3 902.8172 2.626 1.05 
dPC 36:0 790.5761 19.472 1.03 
PC 40:6 878.5913 20.545 1.02 
dPC 34:4 798.5285 20.775 1.01 
dPC 38:8 802.5370 19.578 1.01 
dPC 38:6 850.5600 20.583 1.00 
SM 42:3 855.6594 21.880 0.99 
dPE 34:2 714.5093 13.647 0.98 
Cer 41:2 678.6050 2.831 0.97 
pPE 38:5 750.5450 13.090 0.96 
TAG 58:8 948.8015 2.510 0.95 
SM 36:2 773.5816 22.011 0.95 
pPE 40:7 774.5451 12.965 0.95 
TAG 56:7 922.7866 2.978 0.95 
dPC 34:0 806.5823 21.158 0.94 
TAG 52:6 870.7554 2.510 0.94 
dPC 36:6 778.5388 19.573 0.94 
SM 34:1 749.5820 21.968 0.93 
dPE 36:3 740.5247 13.512 0.92 
dPC 36:5 780.5518 19.975 0.91 
Cer 44:1 722.6675 2.817 0.91 
SM 39:1 773.6537 21.059 0.90 
SM 36:1 775.5968 22.085 0.90 
dPC 34:3 756.5552 19.901 0.90 
dPE 34:1 716.5259 13.687 0.89 
SM 41:3 841.6440 21.866 0.89 
dPC 34:1 804.5748 21.145 0.88 
SM 34:1 749.5720 22.139 0.87 
SM 38:0 761.6439 21.047 0.87 
dPE 36:4 738.5090 13.275 0.87 
SM 29:3 673.5290 22.164 0.87 
HexCer 42:2 854.6725 3.029 0.86 
SM 35:1 717.5906 21.085 0.86 
dPC 38:5 852.5750 20.720 0.86 
dPC 38:5 808.5836 19.536 0.86 
dPC 32:2 774.5295 21.109 0.86 
dPC 38:4 810.6004 19.577 0.86 
dPC 38:6 750.5295 21.341 0.85 
Cer 42:1 694.6359 2.822 0.85 
 
